{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:44:20Z","timestamp":1792590260097,"version":"4.5.0"},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":293,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Case Reports in Rheumatology"],"published-print":{"date-parts":[[2026,1]]},"abstract":"\n Background<\/jats:title>\n Antimelanoma differentiation\u2010associated gene 5 (MDA5) antibody\u2010positive dermatomyositis (MDA5(+) DM) is frequently complicated by interstitial lung disease (ILD) and is associated with a high risk of relapse. Optimal management after relapse remains unclear.<\/jats:p>\n <\/jats:sec>\n \n Case Presentation<\/jats:title>\n A 63\u2010year\u2010old woman presented with characteristic cutaneous manifestations of dermatomyositis and ILD without muscle involvement. She was diagnosed with MDA5(+) DM complicated by ILD and initially treated with high\u2010dose glucocorticoids, tacrolimus, and intravenous cyclophosphamide, resulting in clinical improvement. However, after discontinuation of calcineurin inhibitor therapy due to adverse events, disease relapse occurred, characterized by worsening cutaneous lesions, progression of pulmonary infiltrates, and an increase in anti\u2010MDA5 antibody titers. Subsequently, azathioprine was initiated, and rituximab was administered thereafter. Both clinical and radiological findings improved, and anti\u2010MDA5 antibody titers progressively decreased. Repeated rituximab infusions were followed by stable clinical findings, allowing glucocorticoid tapering without further relapse.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n This case suggests that rituximab combined with azathioprine may be a therapeutic option for disease control after relapse with MDA5(+) DM\u2010ILD.<\/jats:p>\n <\/jats:sec>","DOI":"10.1155\/crrh\/9772488","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:10:27Z","timestamp":1792588227000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rituximab Combined With Azathioprine for Relapsed Anti\u2010MDA5 Antibody\u2010Positive Dermatomyositis With Interstitial Lung Disease: A Case Report"],"prefix":"10.1155","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3191-8619","authenticated-orcid":false,"given":"Hiroki","family":"Ozaki","sequence":"first","affiliation":[{"name":"Department of Rheumatology KKR Takamatsu Hospital 4-18 Tenjinmae Takamatsu 760-0018 Kagawa Japan kkr-ta-hp.gr.jp"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Rheumatology KKR Takamatsu Hospital 4-18 Tenjinmae Takamatsu 760-0018 Kagawa Japan kkr-ta-hp.gr.jp"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"e_1_2_8_1_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key060"},{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000009727"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbae303"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41105"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.210322"},{"key":"e_1_2_8_6_2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3109\/14397595.2015.1014140","article-title":"A Case of Anti-MDA5-Positive Rapidly Progressive Interstitial Lung Disease in a Patient With Clinically Amyopathic Dermatomyositis Ameliorated by Rituximab, in Addition to Standard Immunosuppressive Treatment","volume":"27","author":"Yamaguchi K.","year":"2017","journal-title":"Modern Rheumatology"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.820163"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.37754"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2313070121"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-012-0663-4"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac525"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae011"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-024-01300-8"},{"key":"e_1_2_8_14_2","first-page":"168","article-title":"Rituximab in the Treatment of Anti-MDA5 Dermatomyositis-Associated Interstitial Lung Disease: A Case-Based Literature Review","volume":"1","author":"Nascimento J.","year":"2022","journal-title":"ARP Rheumatol"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-024-07079-z"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2023-0371"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05530-5"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04443-2"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker305"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780240107"},{"key":"e_1_2_8_21_2","volume-title":"The Guide for the Diagnosis and Treatment of Connective Tissue diseases-Associated Interstitial Lung Disease","author":"The Japanese Respiratory Society","year":"2025"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.03.007"}],"container-title":["Case Reports in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/crrh\/9772488","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/crrh\/9772488","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/crrh\/9772488","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:10:28Z","timestamp":1792588228000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/crrh\/9772488"}},"subtitle":[],"editor":[{"given":"Ankit","family":"Dhoundiyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1155\/crrh\/9772488"],"URL":"https:\/\/doi.org\/10.1155\/crrh\/9772488","archive":["Portico"],"relation":{},"ISSN":["2090-6889","2090-6897"],"issn-type":[{"value":"2090-6889","type":"print"},{"value":"2090-6897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2026-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"9772488"}}